Coeptis Therapeutics, Inc.
NASDAQ:COEPBiotechnology
+$0.73 today
- Market cap
- $57.63M
- Beta
- -0.43
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$1.97
Volume 0.18M
Average 0.05M
COEP Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Coeptis Therapeutics, Inc.NASDAQ: COEP
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $4.02M (cash outflow) rose 17.5% year over year, ahead of the +12.6% change in trailing-twelve-month net income. Sequentially, it rose 147.8% from the prior quarter. Over 3 fiscal years it compounded at -31.8% a year.
Context
- Net income amounted to 874.3% of revenue in FY2025.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$14.4M (+20.8%) for the fiscal year ending Dec 2026, a step up from the +9.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$4.02M+147.8% QoQ
- Last fiscal yearDec 2025
- -$11.92M+9.6% YoY
- LTMMar 2026
- -$12.72M+12.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +17.5% | +122.7% | +105.1 pp |
| 1 year | +9.6% | +20.8% | +11.3 pp |
| 3-year CAGR | -31.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (11.92M) USD
- Year-over-year change
- -9.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.92M) | -9.6% |
| FY2024 | 2024-12-31 | (10.88M) | +48.9% |
| FY2023 | 2023-12-31 | (21.27M) | +43.4% |
| FY2022 | 2022-12-31 | (37.57M) | -179.4% |
| FY2021 | 2021-12-31 | (13.45M) | — |
Net Income vs competitors
How COEP compares with its peers on the latest reported figures
- COEP's LTM Mar 2026 net income of $12.72M is the 8th largest of the 9 companies compared; the peer median is $42.75M.
- Its year-over-year change of +12.6% is the 5th highest of 9, against a peer median of +19.0%.
- Net income amounts to 899.5% of revenue for COEP, versus a peer median of 599.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $28.76B | +254398.4% | +1562.8% | — |
| LTM Mar 2026 | $194.97M | +211.8% | +5.9% | 129.0% | |
| LTM Mar 2026 | $107.79M | +391.1% | -58.2% | — | |
| LTM Mar 2026 | $60.96M | -388.6% | -1.9% | 18297.5% | |
| LTM Mar 2026 | $24.54M | +1.8% | -10.4% | 1070.2% | |
| LTM Mar 2026 | $19.52M | -51.9% | -20.5% | 59.6% | |
| LTM Mar 2026 | $19.06M | +36.2% | -28.9% | — | |
| LTM Mar 2026 | $12.72M | +12.6% | -31.8% | 899.5% | |
| LTM Mar 2026 | $9.22M | -26.0% | +130.2% | — | |
| Peer median (excluding COEP) | $42.75M | +19.0% | -6.1% | 599.6% | |
Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.45M) | (37.57M) | (21.27M) | (10.88M) | (11.92M) |
| Depreciation & Amortization | 447.41K | 1M | 1.04M | 1.04M | 1.22M |
| Deferred Income Tax | 5.34M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.9M | 0 | 477.5K | 1.1M | 1.22M |
| Change in Working Capital | (2.98M) | (550.34K) | 1.73M | (125.26K) | (1.46M) |
| Accounts Receivables | 21.79K | (8.08K) | (30.9K) | (234.74K) | (7.35K) |
| Inventory | (422.02K) | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.58M) | (35.07K) | 1.32M | (149.94K) | (381.01K) |
| Other Working Capital | (1M) | (507.19K) | 437.31K | 259.42K | (1.07M) |
| Other Non-Cash Items | 4.26M | 33.25M | 10.79M | 2.21M | 2.34M |
| Operating Cash Flow | (4.49M) | (3.88M) | (7.24M) | (6.65M) | (8.6M) |
| Capital Expenditures | (1.75M) | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.75M) | 0 | 0 | 0 | 0 |
| Debt Repayment | (1.62M) | (2.42M) | (575K) | 1.2M | 771.25K |
| Common Stock Issued | 10.14M | 3.27M | 5.29M | 100K | 12.97M |
| Common Stock Repurchased | (247.17K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (50.9K) | 4.63M | 200K | 500K | 0 |
| Financing Cash Flow | 8.22M | 5.49M | 4.92M | 5.71M | 13.74M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.98M | 1.61M | (2.32M) | (936.25K) | 5.14M |
| Free Cash Flow | (6.24M) | (3.88M) | (7.24M) | (6.65M) | (8.6M) |
Coeptis Therapeutics, Inc.
NASDAQ:COEP
Intrinsic Alpha fair value
Locked
Current Price
$14.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.